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Open access under CC BYThe gut–brain axis refers to the bidirectional communication between the gut and the brain. Four infor-
mation carriers (vagal and spinal afferent neurons, immune mediators such as cytokines, gut hormones
and gut microbiota-derived signalling molecules) transmit information from the gut to the brain, while
autonomic neurons and neuroendocrine factors carry outputs from the brain to the gut. The members
of the neuropeptide Y (NPY) family of biologically active peptides, NPY, peptide YY (PYY) and pancreatic
polypeptide (PP), are expressed by cell systems at distinct levels of the gut–brain axis. PYY and PP are
exclusively expressed by endocrine cells of the digestive system, whereas NPY is found at all levels of
the gut–brain and brain–gut axis. The major systems expressing NPY comprise enteric neurons, primary
afferent neurons, several neuronal pathways throughout the brain and sympathetic neurons. In the diges-
tive tract, NPY and PYY inhibit gastrointestinal motility and electrolyte secretion and in this way modify
the input to the brain. PYY is also inﬂuenced by the intestinal microbiota, and NPY exerts, via stimulation
of Y1 receptors, a proinﬂammatory action. Furthermore, the NPY system protects against distinct behav-
ioural disturbances caused by peripheral immune challenge, ameliorating the acute sickness response
and preventing long-term depression. At the level of the afferent system, NPY inhibits nociceptive input
from the periphery to the spinal cord and brainstem. In the brain, NPY and its receptors (Y1, Y2, Y4, Y5)
play important roles in regulating food intake, energy homeostasis, anxiety, mood and stress resilience. In
addition, PP and PYY signal to the brain to attenuate food intake, anxiety and depression-related behav-
iour. These ﬁndings underscore the important role of the NPY-Y receptor system at several levels of the
gut–brain axis in which NPY, PYY and PP operate both as neural and endocrine messengers.
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262 P. Holzer et al. / Neuropeptides 46 (2012) 261–2741. The gut–brain axis involves neural, immune and endocrine
signalling pathways
The terms ‘‘gut–brain axis’’ and ‘‘brain–gut axis’’ denote the
bidirectional communication between the gut and the brain
(Fig. 1). Apart from the autonomic regulation of digestion by the
central, parasympathetic, sympathetic and enteric nervous sys-
tems as well as by neuroendocrine factors (derived from the adre-
nal medulla and cortex), there is ongoing communication from the
gut to the brain in health and disease. Normally, most information
that is transmitted from the digestive system to the central ner-
vous system does not reach the level of consciousness. However,
visceral information is continuously fed into subcortical regions
of the brain including the limbic system and the autonomic and
neuroendocrine centres in the hypothalamus and brainstem. Un-
der pathological conditions, the input from the gut can reach the
cortex, giving rise to the sensation of nausea, discomfort or pain.
This afferent part of the gut–brain–gut axis has recently been in
the focus of investigation in order to understand why gastrointes-
tinal disease is associated with pain and a number of psychiatric
disturbances including anxiety, neuroticism and depression.
In a traditional view, the gut–brain axis uses 3 major informa-
tion carriers for the communication between the gut and the brain
(Fig. 1): neural messages carried by vagal and spinal afferent neu-
rons, immune messages carried by cytokines, and endocrine mes-
sages carried by gut hormones. Each of these communication
systems is abundantly present in the gastrointestinal tract which
for this reason has been designated as a major neurological (Holzer
et al., 2001), immune (Wittig and Zeitz, 2003) and endocrine
(Ahlman and Nilsson, 2001; Murphy and Bloom, 2006) organ.
The gastrointestinal immune system is important in defending
the body against foreign antigens and pathogens that enter with
the food and in maintaining homeostasis with the extensive micro-
bial community living in the intestine. The gut microbiota and the
gastrointestinal immune system interact with each other via the
gastrointestinal mucosa, and this interaction has important func-
tional implications within and outside the gastrointestinal tract.
It is increasingly emerging that the gut microbiota uses a
fourth information pathway to signal to distant organs including
the brain: apart from modulating the generation of cytokines in
the intestinal immune system they also release signalling
molecules such as lipopolysaccharide (LPS) and peptidoglycanFig. 1. The bidirectional gut–brain axis. Four communication pathways (sensory
neurons, cytokines, gut hormones and microbial factors) signal from the gut to the
brain where they can modify cerebral function and behaviour. Two pathways
(autonomic and neuroendocrine outputs) signal from the brain to the gut. EC, M and
L denote different populations of endocrine cells in the gastrointestinal mucosa.components (Clarke et al., 2010) that can directly act on the cen-
tral nervous system (Fig. 1). Thus, the physiological roles of the
symbiotic gut microﬂora relate not only to the regulation of
digestion, nutrition, mucosal function and intestinal immunity,
but also to metabolic homeostasis, systemic immunity and brain
function (emotion, mood, cognition). With more than 20 hor-
mones produced, the gut is also a major endocrine organ
(Murphy and Bloom, 2006). Formed in specialised endocrine cells
of the gastrointestinal mucosa, gut hormones are involved in the
coordination of digestion, the signalling of hunger and satiety
and the regulation of energy homeostasis, but also in the control
of emotion and mood. Importantly, the 4 communication path-
ways between the gut and the brain do not operate in isolation
but are closely interrelated with each other. For instance, cyto-
kines and gut hormones can act on afferent neurons in the vagus
nerve and in this way send messages to the brain. Understand-
ing the operation of the gut–brain axis in health and disease is
thus not only relevant to gastroenterology but also to neurology
and psychiatry and is likely to reveal important targets for novel
therapeutic strategies.2. Neuropeptide Y, peptide YY and pancreatic polypeptide are
expressed at distinct levels along the gut–brain axis
The members of the neuropeptide Y (NPY) family of biologically
active peptides, NPY, peptide YY (PYY) and pancreatic polypeptide
(PP), are expressed by cell systems at distinct levels of the gut–brain
axis. Consisting of 36 amino acids, NPY, PYY and PP share the PP fold
(hairpin fold) tertiary structural motif. The N-terminus of NPY and
PYY is readily truncated by dipeptidyl peptidase 4 (EC 3.4.14.5)
and other enzymes (e.g., aminopeptidase-P, endopeptidase-24.11),
yielding the fragments NPY3–36 and PYY3–36 (Mentlein et al., 1993;
Medeiros and Turner, 1994). The functional implication of the NPY
family of peptides in the gut–brain communication is corroborated
by the occurrence of 5 NPY receptor types, termed Y1, Y2, Y4, Y5 and
y6 (a human pseudogene), along the gut–brain signalling pathways.
Coupled to pertussis toxin-sensitiveGi/o protein transductionmech-
anisms (Redrobe et al., 2004a; Alexander et al., 2011), the Y receptor
subtypes display characteristic afﬁnities for the different members
of the peptide family and their fragments [Cox, 2007a; Alexander
et al., 2011). While NPY and PYY do not grossly differ in their afﬁn-
ities for the Y1, Y2 and Y5 receptors subtypes, it is particularlyworth
noting that PYY3–36 is a preferred agonist at Y2 receptors while PP
binds preferentially to Y4 receptors (McGowan and Bloom, 2004;
Cox, 2007a; Alexander et al., 2011).2.1. Pancreatic polypeptide
PYY and PP are almost exclusively expressed at the level of the
digestive system, whereas NPY is found at all levels of the gut–brain
and brain–gut axis (Fig. 2). PP, as its name implies, is postprandially
secreted from the pancreas inwhich it is synthesised by endocrine F
cells of the pancreatic islets (Ekblad and Sundler, 2002). In addition,
PP is expressed in a sparse number of endocrine cells in the small
and large intestine, these cells being distinct fromPYY-positive cells
(Cox, 2007a). Both the release of PP and the biological actions of PP
on digestion and food intake, which are preferentially mediated by
Y4 receptors, require signalling in the parasympathetic vagus nerve
(Small and Bloom, 2005; Field et al., 2010). Although Y4 receptors
are expressed in the brain, and Y4 receptor knockout is associated
with reduced anxiety- and depression-related behaviour (Painsipp
et al., 2008b; Tasan et al., 2009), there is a lack of evidence that PP
is produced in the brain, given that the immunoreactivity which
was once believed to reﬂect PP turned out to be NPY (Allen et al.,
1983; DiMaggio et al., 1985).
Fig. 2. The NPY-Y receptor sytem in the gut–brain axis. The graph shows the major
sources of NPY, PYY and PP along the gut–brain axis and the Y receptor subtypes
which mediate the effects of these peptides at the different levels of the gut–brain
axis. The arrow symbols denote stimulation, the tack symbols denote inhibition.
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The major source of PYY in the gut is the endocrine L cell which
occurs most abundantly in the lower gastrointestinal tract (Ekblad
and Sundler, 2002; McGowan and Bloom, 2004; Cox, 2007a,b;
Ueno et al., 2008). In addition, PYY-positive L cells contain glicen-
tin, a proglucagon-derived peptide, glucagon-like peptide-1 and
glucagon-like peptide-2 (Ekblad and Sundler, 2002; Cox, 2007a).
Given that they likewise express gustducin, a taste-related G pro-
tein, as well as bitter and sweet taste receptors, the PYY-containing
L cells are thought to be important chemosensors in the intestine
(Rozengurt et al., 2006). Other, but minor sources of PYY in the
digestive system are enteric neurons of the stomach (Böttcher
et al., 1993) and pancreatic endocrine cells (Cox, 2007b). Since
PYY is postprandially released from intestinal L cells, the peptide
is thought to be a satiety signal, which ﬁts with its effect to reduce
food intake (McGowan and Bloom, 2004). Once released, PYY is in
part cleaved to PYY3–36 which, unlike the parent peptide, is a pref-
erential agonist at Y2 receptors (Small and Bloom, 2005; Cox,
2007b). Evidence for the expression of PYY in the brain is compar-
atively sparse. Morimoto et al. (2008) used radioimmunoassay,
immunocytochemistry and reverse transcription polymerase chain
reaction to ﬁnd expression of PYY in the human brain and pituitary
gland. In the rodent brain, PYY-positive neurons have been local-
ised to the hypothalamus, pons, medulla and spinal cord (Ekblad
and Sundler, 2002).2.3. Neuropeptide Y
In contrast to PP and PYY, NPY is expressed at all levels of the
gut–brain and brain–gut axis, the major systems expressing this
peptide being enteric neurons, primary afferent neurons, several
neuronal pathways throughout the brain and sympathetic neurons
(Fig. 2). Within the gut, the major source of NPY is constituted by
enteric neurons. NPY occurs in the two major enteric nerve plex-
uses and has been localised to distinct interneurons and descend-
ing inhibitory motoneurons of the myenteric plexus as well as to
noncholinergic secretomotor neurons of the submucosal plexus
(Cox, 2007a). In the inhibitory motor neurons, NPY is frequently
colocalised with vasoactive intestinal polypeptide and nitric oxidesynthase (Schicho et al., 2003; Cox, 2007a). In addition to enteric
neurons, NPY is also expressed in postganglionic sympathetic neu-
rons in which it is colocalised with noradrenaline and adenosine
triphosphate (Cox, 2007a; Holzer, 2012). NPY is preferentially
found in sympathetic neurons supplying the vascular system but
is largely absent from sympathetic neurons innervating the gastro-
intestinal mucosa (Lomax et al., 2010).
A further but very minor source of NPY in the gut is provided by
primary afferent neurons originating in the dorsal root ganglia
(Brumovsky et al., 2007). Under physiological conditions the NPY
content of these neurons is very low, but under conditions of nerve
injury the expression of NPY can be markedly upregulated, partic-
ularly in medium- and large-sized sensory neurons (Brumovsky
et al., 2007). Nerve injury and inﬂammation also has an impact
on the presence of Y1 and Y2 receptors in primary afferent neu-
rons, these receptors being primarily expressed by small, presum-
ably nociceptive sensory neurons (Brumovsky et al., 2007). Within
the spinal cord there is an abundant NPY-containing neuropil
which is made of at least 3 different neuron populations: inhibitory
interneurons also containing c-aminobutyric acid (GABA),
descending noradrenergic neurons originating in the locus coeru-
leus, and primary afferent nerve endings (Brumovsky et al.,
2007). The abundance of NPY in the spinal cord is matched by an
extensive distribution of Y1 receptors which in the rat and mouse
have been localised to 7 distinct types of neurons within the dorsal
horn of the spinal cord (Brumovsky et al., 2007). By contrast, Y2
receptors appear to occur exclusively on the central terminals of
primary afferent neurons in the superﬁcial laminae of the spinal
cord (Brumovsky et al., 2007).
Within the brain, NPY is the most abundant neuropeptide, being
expressed by a multitude of neuronal systems in regions spanning
from the medullary brainstem to the cerebral cortex. In the context
of the gut–brain axis it is particularly worth noting that NPY occurs
in the nucleus of the solitary tract and ventrolateral medulla, peri-
aqueductal grey and locus coeruleus, paraventricular nucleus of
the thalamus, hypothalamus (arcuate nucleus, paraventricular nu-
cleus and other regions), septum, hippocampus, amygdala, basal
ganglia, nucleus accumbens and cerebral cortex (Wettstein et al.,
1995; Kask et al., 2002; Eaton et al., 2007). Several important path-
ways utilising NPY as a neurotransmitter have been identiﬁed.
These include noradrenergic neurons originating in the locus coe-
ruleus of the brainstem and issuing both ascending and descending
projections in the central nervous system, neurons expressing both
NPY and agouti-related protein (AgRP) originating in the arcuate
nucleus of the hypothalamus, and distinct pathways operating in
the limbic system (Wettstein et al., 1995; Kask et al., 2002; Eaton
et al., 2007). The major receptor subtypes which NPY acts on in
the brain are the Y1 and Y2 receptors, the localization of which
are discussed when the functional implications of NPY in the cere-
bral part of the gut–brain axis are considered. While Y1 and Y2
receptors are widely distributed in the central nervous system,
the localization of Y4 and Y5 receptors is restricted to particular re-
gions of the brain such as nucleus of the solitary tract, area pos-
trema, nucleus ambiguus, hypothalamus, thalamus and amygdala
(Kask et al., 2002; McGowan and Bloom, 2004; Eaton et al., 2007;
Tasan et al., 2009).3. NPY, PYY and PP play speciﬁc roles at distinct levels of the
gut–brain axis
3.1. NPY, PYY and PP inhibit gastrointestinal motility and secretion and
thereby alter the input to the brain
The gut hormones PYY and PP and the enteric neuropeptide NPY
subserve many functions in the regulation of digestion, which have
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Thus, only a brief summary of their functional implications within
the digestive system is given here. These implications cannot go
unnoticed, however, because any change in gastrointestinal func-
tion will also issue messages sent to the brain (Fig. 2), either via
a neural route or via the blood stream (gut hormones, cytokines).
It is also obvious that the functional implications of NPY, PYY
and PP depend critically on the expression of different Y receptor
subtypes by the control and effector systems of digestion.
PP is released from the endocrine pancreas following a meal and
acts preferentially via Y4 and Y5 receptors. It inhibits gastric emp-
tying through an action that involves the vagus nerve; this effect
may in part account for its ability to reduce appetite, an effect that
also depends on intact vagal signalling (Murphy and Bloom, 2006;
Field et al., 2010). By targeting Y4 receptors on the intestinal epi-
thelium, PP can also inhibit intestinal electrolyte and water secre-
tion (Tough et al., 2006). In addition, PP has an inhibitory action on
intestinal motor activity and peristalsis (Fujimiya and Inui, 2000),
an effect that in the guinea-pig small intestine is mediated by en-
teric neurons (Holzer et al., 1986).
PYY is released from intestinal L cells following a meal in pro-
portion to energy intake, particularly by fat and protein (Field
et al., 2010). The meal-evoked release of PYY occurs long before
the nutrients have reached the lower gut where the PYY-
expressing L cells are most abundant, which indicates that a neural
mechanism including the vagus nerve is involved (Fu-Cheng et al.,
1997; Cox, 2007b). Gastric acid secretion, cholecystokinin, bile
acids and free fatty acids of a particular length (C12) also stimulate
the release of PYY (McGowan and Bloom, 2004; Feltrin et al., 2006)
as do short chain fatty acids (SCFAs), particularly butyrate, which
are produced through fermentation of indigestible carbohydrates
by the colonic microbiota (Cherbut et al., 1998). Once released, part
of PYY is enzymatically cleaved to PYY3–36, the major circulating
form of PYY (Mentlein et al., 1993). This transformation is paral-
leled by a shift in the Y receptor subtypes stimulated by the
peptide: while the full length peptide activates Y1, Y2 and Y5
receptors, the effects of PYY3–36 are preferentially mediated by
Y2 and, to some extent, Y5 receptors (Mentlein et al., 1993;
McGowan and Bloom, 2004; Cox, 2007b).
PYY and PYY3–36 have profound effects on gastrointestinal
motility and secretion. The inhibitory action of PYY and PYY3–36
on gut function is mediated by 3 major Y receptor subtypes: Y1
receptors on enterocytes, myenteric and submucosal neurons and
endothelial cells, Y2 receptors on myenteric and submucosal neu-
rons, extrinsic primary afferent nerve ﬁbres, and Y4 receptors on
enterocytes (Cox, 2007a,b; Wang et al., 2010). Plasma concentra-
tions roughly equivalent to postprandial levels inhibit gastric acid
secretion, gastric emptying, the cephalic phase of gallbladder con-
traction and mouth-to-caecum transit time (Field et al., 2010). The
inhibition of gastric acid secretion involves Y1 and Y2 receptors
and is mediated both by an action in the brainstem and stomach
(Yang, 2002), while the effect of PYY3–36 to increase gastric pres-
sure via stimulation of Y2 receptors does not involve the vagus
nerve (Janssen et al., 2012). PYY released by SCFAs (administered
exogenously or produced by the intestinal microbiota) inhibits gas-
trointestinal motility and electrolyte and water secretion by neural
and non-neural mechanisms (Cox, 2007b). In addition, PYY pro-
motes mucosal cell differentiation (Halldén and Aponte, 1997).
In physiological terms, PYY is thought to be a major mediator of
ileal and colonic brakes which are set into operation when fat
reaches the lower gut: the brakes slow gastric emptying and intes-
tinal transit, which in conjunction with the antisecretory action of
PYY facilitates nutrient absorption (Pironi et al., 1993; Lin et al.,
1996; Nightingale et al., 1996; Van Citters and Lin, 2006; Cox,
2007b). The effect of PYY and PYY3–36 to inhibit colonic transit in
the mouse is mediated by Y2 receptors on the enteric nervoussystem (Wang et al., 2010; Tough et al., 2011). There is also grow-
ing evidence that PYY and NPY exert a tonic inﬂuence on gastroin-
testinal motor and secretory activity. While Y2 receptor
antagonists per se do not alter gastric motor tone (Janssen et al.,
2012), Y1 and Y2 receptor antagonism as well as PYY and NPY
knockout modify colonic ion transport and motility (Tough et al.,
2011). The pertinent ﬁndings indicate that, both in the human
and mouse colonic mucosa, PYY and NPY exert a tonic antisecre-
tory effect mediated by epithelial Y1 and neural Y2 receptors. Co-
lonic transit is tonically accelerated by Y1 receptor stimulation and
tonically inhibited by Y2 receptor stimulation (Tough et al., 2011).
Emerging evidence also suggests that PYY shares some of the
incretin-like activity of glucagon-like peptide-1, another gut hor-
mone derived from enteroendocrine L cells (Cox et al., 2010). These
cells use G protein-coupled receptors (GPRs) such as GPR119 to re-
spond to luminal nutrients and to release glucagon-like peptide-1
as well as PYY. The effect of GPR119 agonism to improve glucose
tolerance in association with enhanced glucose-induced circulat-
ing insulin concentrations is mediated by PYY (Cox et al., 2010).
This newly discovered role in glucose homeostasis makes PYY a
potentially useful target for the treatment of diabetes and obesity.
The gastrointestinal Y receptor subtypes are prominently tar-
geted by NPY which in the gut is expressed by inhibitory enteric
motor pathways, secretomotor neurons and sympathetic neurons.
NPY inhibits gastrointestinal motility as well as electrolyte and
water secretion, and its inhibitory action on intestinal Cl secretion
is seen in all regions of the intestine (Saria and Beubler, 1985;
Hubel and Renquist, 1986; Holzer-Petsche et al., 1991; Cox, 2007a).
Although Y2 receptors play a major role in the antisecretory/proab-
sorptive effect of NPY and PYY, Y1 receptors on secretomotor neu-
rons and epithelial cells, and Y4 receptors on enterocytes are also
likely to contribute (Cox and Tough, 2002; Tough et al., 2006;
Cox, 2007a). The prominent location of Y receptor subtypes on en-
teric neurons is also responsible for the inhibitory effect of NPY on
gastrointestinal motility (Fujimiya and Inui, 2000). Peristalsis in
the guinea-pig small intestine is depressed by NPY through inter-
ruption of excitatory pathways in the enteric nervous system
(Holzer et al., 1987).
3.2. NPY interacts with the immune system and promotes
gastrointestinal inﬂammation
There is ample evidence that NPY is among the neuropeptides
which have a distinct impact on immune function, within and out-
side the gastrointestinal tract (Bedoui et al., 2007; Wheway et al.,
2007a; Dimitrijevic´ and Stanojevic´, in press). This is particularly
true for NPY released from the sympathetic nerve ﬁbres which in
lymphoid tissues form close contacts with immune cells. Following
release, NPY acts on Y receptors (notably of the Y1, Y2, Y4 and Y5
subtype) expressed by distinct classes of immune cells (e.g., den-
dritic cells, mononuclear cells, macrophages, granulocytes, T and
B lymphocytes) to modify their activity (Wheway et al., 2005,
2007b; Mitic´ et al., 2011; Dimitrijevic´ and Stanojevic´, in press).
However, NPY acts not only as a neuroimmune transmitter but also
as a paracrine or autocrine immune mediator, given that immune
cells (e.g., B and T lymphocytes, macrophages) themselves are
capable of producing and releasing NPY (Wheway et al., 2007a,b).
In this way NPY can affect both innate and adaptive immunity,
leading to either immune activation or suppression depending on
its concentration, the Y receptors activated and cell types involved
(Bedoui et al., 2007; Wheway et al., 2007a; Dimitrijevic´ and
Stanojevic´, in press). The effects of NPY include modulation of im-
mune cell trafﬁcking, T helper cell differentiation, cytokine secre-
tion, natural killer cell activity, phagocytosis and production of
reactive oxygen species (Hernanz et al., 1996; Bedoui et al.,
2007; Wheway et al., 2007a; Dimitrijevic´ and Stanojevic´, in press).
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ulating inﬂammatory processes, given that NPY-containing nerve
ﬁbres are in close contact with immune cells such as IgA-producing
lymphocytes in the mouse ileum lamina propria (Shibata et al.,
2008). The proliferation of lymphocytes from the human colonic
lamina propria is also stimulated by NPY (Elitsur et al., 1994).
The ability of NPY to promote colonic inﬂammation is supported
by several lines of evidence. Firstly, NPY knockout mice are largely
resistant to the induction of dextran sulfate sodium (DSS)-induced
colitis (Chandrasekharan et al., 2008; Painsipp et al., 2011a). Sec-
ondly, the result of NPY deletion is reproduced by treatment with
a NPY antisense oligodeoxynucleotide (Pang et al., 2010) and by
knockout or antagonism of Y1 receptors (Hassani et al., 2005),
which demonstrates that the Y1 receptor plays a pivotal role in
the proinﬂammatory effect of NPY. The antiinﬂammatory pheno-
type of Y1 receptor knockout mice results from a defect in anti-
gen-presenting cell function, a reduction of TNF-a and IL-12
production by macrophages, and a decrease in the number of effec-
tor T cells (Wheway et al., 2005). Thirdly, experimentally induced
colitis is associated with an increase in the colonic synthesis of
NPY (Chandrasekharan et al., 2008; Pang et al., 2010; Baticic
et al., 2011), a reduction of colonic Y1 receptor expression and a
loss of the antisecretory action of NPY in the colon (Klompus
et al., 2010). In contrast, the colonic levels of PYY are decreased
in rats with DSS-induced colitis (Hirotani et al., 2008). These exper-
imental data are in line with a decrease of colonic PYY levels in pa-
tients with inﬂammatory bowel disease (Tari et al., 1988; El-Salhy
et al., 1997; Schmidt et al., 2005), while circulating levels of PYY
and NPY are enhanced (Adrian et al., 1986; Straub et al., 2002).
Given that NPY is an activator of antigen-presenting cell func-
tion and a negative regulator of T cell function (Wheway et al.,
2005, 2007a,b; Dimitrijevic´ and Stanojevic´, in press), the impact
of NPY on gut inﬂammation is complex and involves a variety of
down-stream mechanisms. For instance, NPY enhances the expres-
sion of neuronal nitric oxide synthase which is a determinant of
oxidative stress and subsequent inﬂammation (Chandrasekharan
et al., 2008). It is conceivable that PYY and PP also inﬂuence the
intestinal immune system, acting via the same Y receptors as
NPY. The proinﬂammatory effect of NPY could in part be coun-
ter-regulated by the vasoconstrictor effect of the peptide, given
that the sympathetic constriction of splanchnic resistance vessels
is co-mediated by the sympathetic triad adenosine triphosphate
(ATP), noradrenaline and NPY (Holzer, 2012). In addition, NPY is
able to potentiate the constrictor effect of noradrenaline and ATP.
Both the vasoconstrictor response to NPY and its action to augment
noradrenaline- and ATP-induced mesenteric vasoconstriction are
mediated by postjunctional Y1 receptors (Holzer, 2012).
3.3. The impact of the gut microbiota on the gut–brain axis may
involve NPY and PYY
Endocrine cells in the gut mucosa are in direct contact with the
intestinal microbiota, and there is emerging evidence that an inter-
action between these systems has an impact on the satietogenic
and metabolic effects of gut hormones including PYY (Cani et al.,
2009; Delzenne et al., 2011). In order to comprehend the implica-
tions of this relationship a brief survey of the emerging roles of
the gut microbiota in the gut–brain axis is in place. The intestinal
microﬂora is relevant to nutrition, digestion, metabolic homeosta-
sis, local and systemic immune function, and neurobiological
homeostasis (Melgar and Shanahan, 2010; Cani and Delzenne,
2011; Grenham et al., 2011; DuPont and DuPont, 2011; Bercik
et al., 2012). It has even been shown that, within a critical window
of time, the presence of commensal gut microbiota is required for
normal brain development and synaptogenesis (Heijtz et al.,
2011). A change in the composition of the gut microbiota is animportant factor leading to gastrointestinal immune activation
(Shanahan, 2011). Likewise, dysbiosis of the intestinal microﬂora
(Krogius-Kurikka et al., 2009; Tana et al., 2010; Jeffery et al.,
2012) and upregulation of mucosal Toll-like receptors (McKernan
et al., 2011) have been implicated in the aetiology of irritable bowel
syndrome (IBS). Analysis of the faecal microbiota reveals subgroups
of IBS patients who either have a normal composition of gut micro-
biota or show substantial microbiota-wide changes characterised
by an increased Firmicutes:Bacteroidetes ratio (Jeffery et al., 2012).
A number of clinical variables, including rectal pain threshold and
depression, are associatedwith distinctmicrobial signatures, which
may have a bearing on the pathophysiology and diagnosis of this
functional gastrointestinal disorder (Jeffery et al., 2012).
The contention that intestinal dysbiosis, as has been found to
occur in patients with IBS (Krogius-Kurikka et al., 2009; Tana
et al., 2010; Jeffery et al., 2012), contributes to the psychiatric
comorbidity seen in these patients is backed by three lines of
experimental investigation: experimental changes in the intestinal
microbiota composition, neurobiological and behavioural pheno-
typing of germ-free mice, and analysis of the systemic effects of
probiotics. Antibiotic-induced dysbiosis of the intestinal microﬂora
increases the expression of brain-derived neurotrophic factor in
the hippocampus and enhances exploratory behaviour (Bercik
et al., 2011a). Memory is impaired in germ-free mice, and exposure
to stress combined with Citrobacter rodentium infection causes pro-
longed memory dysfunction (Gareau et al., 2011). Long-term treat-
ment of mice with the probiotic Lactobacillus rhamnosus has a
signiﬁcant impact on brain neurochemistry, reduces anxiety- and
depression-related behaviour and improves stress coping (Bravo
et al., 2011). These behavioural effects are mediated by the vagus
nerve and are associated with region-dependent alterations in
the cerebral GABA receptor expression (Bravo et al., 2011).
The impact of intestinal dysbiosis on brain function takes place
independently of inﬂammation and does not depend on the auto-
nomic nervous system (Bercik et al., 2011a). In addressing the
question as to how gastrointestinal microbiota signal to the brain,
several possibilities come to mind: constituents of the microbiota
themselves (Clarke et al., 2010), sensory neurons, circulating cyto-
kines, and gut hormones. Administration of Escherichia coli LPS into
the rat jejunum causes vagal afferent input to the nucleus of the
solitary tract (Gakis et al., 2009) as does intraperitoneal injection
of interleukin-1b or tumour necrosis factor-a (Holzer et al.,
2004). It is worth noting that the anxiolytic and antidepressant ef-
fects of probiotics are blocked by vagotomy (Bercik et al., 2011b;
Bravo et al., 2011).
There is some evidence that the NPY–PYY system has an im-
pact on the composition and function of the gut microbiota and
its relevance to the gut–brain axis. For instance, NPY has been
found to exhibit a direct antimicrobial effect against various
gut bacteria including E. coli, Enterococcus faecalis, and Lactobacil-
lus acidophilus (El Karim et al., 2008). A relationship between the
gut microbiota and the enteroendocrine PYY system can be
envisaged if the role of gut microbiota in the fermentation of
nondigestible carbohydrates is considered. While the human
gut has a limited repertoire of glycoside hydrolases, the gut mic-
robiota synthesises a large arsenal of these enzymes which pro-
cess complex dietary carbohydrates to SCFAs, principally acetate,
propionate, and butyrate (Samuel et al., 2008). Fermentation of
prebiotic ﬁbre also promotes satiety and lowers hunger and en-
ergy intake, an effect that is associated with enhanced release of
glucagon-like peptide-1 and PYY from the gut (Cani et al., 2009;
Cani and Delzenne, 2011; Delzenne et al., 2011). Since PYY is a
satiety factor, it is conceivable that it contributes to the prebi-
otic-induced reduction of food intake. The effect of PYY on en-
ergy homeostasis, along with that of PP and NPY, is dealt with
in a separate section of this review.
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and PYY-releasing L cells are still little understood. On the one
hand, prebiotic supplementation may lead to a long-term change
in gut microbiota composition. On the other hand, SCFAs which
have many effects on gut mucosal physiology (Guilloteau et al.,
2010; Macia et al., 2012) may directly interact with the PYY-
producing cells since Gpr41, a G protein-coupled receptor for
SCFAs, is expressed by a subset of enteroendocrine cells in the
gut epithelium (Samuel et al., 2008). Colonisation of the mouse co-
lon with a fermentative humanmicrobial community increases the
plasma level of PYY, an effect that is blunted by knockout of Gpr41.
Gpr41 deﬁciency is associated with a reduced expression of PYY, an
increase in intestinal transit rate and an attenuation of energy
harvest (Samuel et al., 2008). Microbiota-fermented SCFAs acting
via Gpr41 on PYY-expressing L cells could thus be an important
link in microbial–host communication.
3.4. The NPY system protects against distinct behavioural disturbances
caused by peripheral immune challenge
Infection and inﬂammation are increasingly recognised to con-
tribute to the pathogenesis of mood disorders including major
depression (Raison et al., 2006; Dantzer et al., 2008; Maes et al.,
2012). Peripheral induction of cytokines by infection or cancer of-
ten induces a sequence of behavioural alterations comprising sick-
ness followed by depression, these effects being abrogated by
cytokine antagonists or cytokine synthesis blockers (Yirmiya,
1996; Anisman et al., 2005; Dunn et al., 2005; Raison et al.,
2006; Dantzer et al., 2008; Pyter et al., 2009). Emerging clinical evi-
dence suggests that activation of the intestinal immune system by
constituents of the intestinal microbiota can give rise to a similar
syndrome of behavioural alterations (Maes et al., 2009). Bacterial
cell wall components such as LPS may penetrate the intestinal
mucosal barrier once it has become leaky (Maes et al., 2012) as a
result of stress, low-grade intestinal inﬂammation or a dysbalance
between the intestinal microbiota and the intestinal immune sys-
tem. As a consequence, translocation of bacterial cell wall constit-
uents or intestinal bacteria themselves across the intestinal
mucosa has been proposed to be a pathogenetic factor in psychiat-
ric diseases such as depression and chronic fatigue syndrome
(Maes et al., 2009). In support of this hypothesis, the serum con-
centrations of immunoglobulin A and M against lipopolysaccharide
of gram-negative enterobacteria are increased in patients with ma-
jor depression (Maes et al., 2012).
Experimentally, the impact of peripheral immune challenge on
brain function and behaviour can be modelled by systemic admin-
istration of LPS or Bacille Calmette-Guérin (BCG). These interven-
tions induce the formation of cytokines and evoke a behavioural
syndrome that follows a distinct time course (Yirmiya, 1996;
Dantzer et al., 2008; Moreau et al., 2008). Initially, a response
termed ‘‘sickness behaviour’’ is observed, including anorexia,
reduction of locomotion and a decrease in social interaction. Once
the sickness behaviour in terms of anorexia and sedation is over,
behavioural symptoms indicative of depression such as anhedonia
and passive stress coping may persist for several weeks (Frenois
et al., 2007; Moreau et al., 2008; Painsipp et al., 2011b). The signal-
ling pathways whereby peripheral immune challenge alters brain
mechanisms involve proinﬂammatory cytokines such interleukin-
6, tumour necrosis factor-a and interferon-c, which reach the brain
via the bloodstream but also excite vagal afferent neurons and lead
to the expression of cytokines by cerebral microglial cells and
astrocytes (Anisman et al., 2005; Dunn et al., 2005; Raison et al.,
2006; Dantzer et al., 2008).
The impact of peripheral immune challenge on brain function
and behaviour involves several brain nuclei (Frenois et al., 2007)
that express NPY and various Y receptors. NPY is involved in theregulation of emotional-affective behaviour (Heilig, 2004; Redrobe
et al., 2004a; Morales-Medina et al., 2010), and there is indirect evi-
dence that NPY-expressing neurons in the arcuate and paraventric-
ular nuclei of the hypothalamus counteract the behavioural
responses to immune stress and infection (McCarthy et al., 1995;
Sonti et al., 1996; McMahon et al., 1999). This implication has been
borne out in knockout experiments in which the cerebral NPY-Y
receptor system has been found to protect against distinct behav-
ioural disturbances in response to peripheral immune challenge.
For instance, deletion of NPY as well as NPY plus PYY aggravates
the BCG-induced loss of body weight andmarkedly delays recovery
from this weight loss (Painsipp et al., submitted for publication).
This ﬁnding attests to an important physiological role of NPY and
PYY in maintaining energy homeostasis in the face of infection
and immune stimulation (Painsipp et al., submitted for publication).
Analogous observations have been made when the acute sick-
ness and delayed depression-like responses to LPS are analysed
in Y2 and Y4 knockout mice. Thus, Y2 receptor knockout mice
are particularly susceptible to the acute action of LPS to attenuate
locomotion and suppress social interaction (Painsipp et al., 2008a).
In contrast, the LPS-induced rise of temperature and circulating
corticosterone is suppressed by Y2 receptor knockout (Painsipp
et al., 2008a). The short-term effect of LPS to enhance anxiety is en-
hanced in Y2 and Y4 receptor knockout mice (Painsipp et al.,
2008a, 2010a). In Y4 receptor knockout mice, the anxiogenic re-
sponse to LPS persists at least for 4 weeks post-treatment by which
time it has waned in WT mice (Painsipp et al., 2010a). Depression-
related behaviour is enhanced 1 day post-LPS in control and Y2
receptor knockout mice, but not in Y4 receptor knockout mice.
Four weeks post-treatment the depressogenic effect of LPS has
waned in wild-type mice, but is maintained in Y2 receptor knock-
out mice and ﬁrst observed in Y4 receptor knockout mice (Painsipp
et al., 2010a). Thus, knockout of Y2 and/or Y4 receptors unmasks
the ability of immune challenge with LPS to cause a delayed and
prolonged increase in anxiety- and/or depression-like behaviour.
These ﬁndings suggest that NPY acting via Y2 and Y4 receptors
prevents the development of long-term anxiety- and depression-
like behaviour caused by immune challenge (Painsipp et al.,
2010a).
3.5. NPY inhibits nociceptive transmission in the spinal cord and
brainstem
Abdominal pain arises from various conditions such as ulcera-
tion, perforation, muscle spasms, intestinal obstruction and inﬂam-
mation (e.g., oesophagitis, gastritis, colitis). As in other tissues,
inﬂammation has a major impact on the nociceptive system, and
the pain associated with post-infectious IBS is likewise associated
with low-grade inﬂammation and immune activation in the colo-
nic mucosa. The propensity of the gut towards inﬂammation is re-
lated to its task to defend the body against antigens and pathogens,
and to the huge microbiota community that inhabits the colon and
is balanced by the local immune system. Apart from its adverse im-
pact on bowel function, inﬂammation causes hyperalgesia and
pain, given that inﬂammatory mediators sensitise nociceptive
pathways (Holzer and Holzer-Petsche, 2009; Hughes et al., 2009;
Knowles and Aziz, 2009). Hypersensitivity to pain stimuli can
develop in all components of the sensory innervation of the gastro-
intestinal tract, which is unique since 2 major populations of sen-
sory neurons with input to the central nervous system are present:
spinal afferent neurons originating from the dorsal root ganglia,
and vagal afferent neurons originating primarily from the nodose
ganglion. Neurophysiologically distinct populations of these affer-
ent neurons supply the mesentery, serosa, muscularis and mucosa
of the alimentary canal and differ in their sensory modalities
(Hughes et al., 2009; Knowles and Aziz, 2009).
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terminate in the spinal cord where interneurons and descending
noradrenergic neurons express appreciable amounts of NPY
(Brumovsky et al., 2007; Smith et al., 2007). An abundant occur-
rence of Y1 and Y2 receptors in the spinal cord enables NPY to play
an important role in the processing of incoming nociceptive infor-
mation. Germ-line knockout of Y1 receptors or conditional knock-
down of NPY is associated with thermal, chemical and mechanical
hyperalgesia (Naveilhan et al., 2001; Shi et al., 2006; Painsipp et al.,
2010b; Solway et al., 2011). Inﬂammation-independent pain
evoked by intraperitoneal injection of MgSO4 and inﬂammation-
dependent visceral pain evoked by intraperitoneal injection of ace-
tic acid is likewise exacerbated by Y1 receptor deletion (Naveilhan
et al., 2001). Peripheral inﬂammation leads to an upregulation of
Y1 receptors in spinal afferent neurons and in the dorsal horn of
the spinal cord (Ji et al., 1994). However, these studies have pri-
marily focused on somatic pain, and it awaits to be explored
whether the antinociceptive role of NPY in the spinal cord also
holds true for visceral pain. Two major mechanisms whereby
NPY controls pain transmission in the spinal cord have been envis-
aged: inhibition of transmitter release from the terminals of pri-
mary afferent neurons, mediated primarily by Y2 receptors, and
inhibition of postsynaptic neurons in the dorsal horn, mediated
primarily by Y1 receptors (Brumovsky et al., 2007; Smith et al.,
2007).
Apart from spinal sensory neurons, vagal afferent neurons have
also been established to play a role in visceral nociception, partic-
ularly in visceral chemonociception. Thus, vagal afferents signal
intragastric acid challenge to the nucleus tractus solitarii (NTS)
as visualised by expression of c-Fos, a marker of neuronal activa-
tion, and evoke behavioural reactions indicative of pain (Schuligoi
et al., 1998; Lamb et al., 2003). Y2 and Y4 receptors are the Y recep-
tor subtypes prevailing in the rat NTS (Gustafson et al., 1997;
Larsen and Kristensen, 1997; Dumont et al., 1998; Parker and
Herzog, 1999), and gene deletion experiments have revealed that
endogenous NPY acting via Y2 and Y4 receptors controls the
chemonociceptive input from the stomach to the brainstem
(Wultsch et al., 2005). Speciﬁcally, the intragastric acid-evoked
expression of c-Fos in the NTS is enhanced in Y2 and Y4 receptor
knockout mice. Further analysis has shown that NPY acting via
Y2 and Y4 receptors depresses the gastric input to the NTS by a
central site of action (Wultsch et al., 2005).
NPY may be both a transmitter and modulator of the communi-
cation between vagal afferents and their projection neurons in the
NTS, since this neuropeptide (Lawrence et al., 1998) as well as Y1,
Y2 and Y4 receptors (Ergene et al., 1993; Gustafson et al., 1997;
Larsen and Kristensen, 1997; Zhang et al., 1997; Dumont et al.,
1998; Parker and Herzog, 1999; Kopp et al., 2002) are expressed
by certain vagal afferents and NTS neurons. While the Y2 recep-
tor-mediated effects of NPY arise most likely from a presynaptic
site of action on vagal afferents (Ergene et al., 1993; Zhang et al.,
1997), the site of Y4 receptors in the control of afferent input to
the brainstem remains to be analysed. The role of NPY in the
gut–brain axis at the level of the brainstem is not limited to the
control of chemonociceptive input but also extends to the reﬂex
control of visceral functions. Thus, stimulation of Y receptors in
the brainstem inﬂuences gastric motility, acid secretion and muco-
sal integrity (Chen et al., 1997; Yang et al., 1999; Yang, 2002).
3.6. NPY may protect from the impact of stress on the gut–brain axis
Physical stress such as infection, immune challenge, inﬂamma-
tion and pain as well as psychosocial stress have a marked impact
on brain function and behaviour. Chronic abdominal pain, which is
a common symptom of inﬂammatory bowel disease and functional
gastrointestinal disorders (Knowles and Aziz, 2009), is frequentlyaccompanied by anxiety and mood disorders (Mawdsley and
Rampton, 2005; Graff et al., 2009; Taché and Bernstein, 2009),
and psychological stress and depression go often hand in hand
with an aggravation of intestinal inﬂammation (Mittermaier
et al., 2004; Ghia et al., 2009). Psychosocial stress is also known
to trigger or exacerbate visceral pain, and IBS is frequently associ-
ated with stress hypersensitivity and impaired stress coping (Levy
et al., 2006; Longstreth et al., 2006; Nicholl et al., 2008; Spiller and
Garsed, 2009). Neuroanatomical and functional brain imaging
studies indicate that noxious signals from the body are processed
in brain areas that are closely interrelated with the neuronal cir-
cuitry relevant to anxiety and mood (Mayer et al., 2008). Experi-
mental studies conﬁrm that gastrointestinal inﬂammation alters
emotional-affective behaviour in a gender-dependent manner
(Painsipp et al., 2007, 2011a; Goehler et al., 2008). Thus, experi-
mental gastritis is associated with an increase of anxiety in female
mice (Painsipp et al., 2007), whereas experimental colitis enhances
anxiety-related behaviour in male and depression-like behaviour
in female mice (Painsipp et al., 2011a).
Since NPY plays a role in pain, mood and stress coping, it may
also be relevant to the impact of stress on the gut–brain axis. This
argument takes account of a large body of experimental and clini-
cal evidence that NPY is an important regulator of emotional pro-
cessing. NPY as well as Y1, Y2 and Y5 receptors are widely
expressed in cerebral areas critical to the regulation of anxiety,
mood, cognition and stress resilience (Kask et al., 2002; Heilig,
2004; Redrobe et al., 2004a; Eva et al., 2006; Morales-Medina
et al., 2010). The expression of NPY in the human brain is related
to polymorphisms in the NPY gene, and a low NPY expression
genotype is associated with negative emotional processing, dimin-
ished stress resilience, a risk for major depression, and a reduced
antidepressant treatment response (Zhou et al., 2008; Domschke
et al., 2010; Mickey et al., 2011). Exposure of individuals with a
low NPY expression genotype to negative stimuli causes an exag-
gerated activation of the amygdala, medial prefrontal cortex and
anterior cingulate cortex (Zhou et al., 2008; Domschke et al.,
2010; Mickey et al., 2011). The concentration of NPY in the cere-
brospinal ﬂuid and plasma is reduced in patients with post-
traumatic stress disorder, while trauma-exposed individuals who
do not develop or have recovered from post-traumatic stress
disorder have enhanced plasma levels of NPY (Morgan et al.,
2003; Yehuda et al., 2006; Sah et al., 2009). It is argued, therefore,
that the cerebrospinal and plasma concentration of NPY is a biolog-
ical correlate of resilience to or recovery from the adverse effects of
stress (Yehuda et al., 2006).
Animal experiments conﬁrm that NPY is involved in the emo-
tional processing of stress. The amygdala, which is a key brain re-
gion coordinating behavioural stress responses (McEwen, 2007),
contains high levels of NPY and Y1, Y2, Y4 and Y5 receptors (Parker
and Herzog, 1999; Kask et al., 2002; Kopp et al., 2002; Wolak et al.,
2003; Tasan et al., 2009). Intracerebroventricular and intra-
amygdalar administration as well as amygdalar overexpression of
NPY have an anxiolytic effect which is primarily mediated by Y1
receptors, although other receptors (e.g., Y5) may also contribute
(Heilig et al., 1989; Karlsson et al., 2005; Sørensen et al., 2004;
Primeaux et al., 2005; Fendt et al., 2009). The action of NPY to
attenuate anxiety- and depression-related behaviour and improve
stress coping is corroborated by the anxiogenic and depressive
phenotype of NPY and Y1 receptor knockout mice (Bannon et al.,
2000; Karl et al., 2006, 2008; Painsipp et al., 2011a). In contrast, ge-
netic deletion or pharmacological antagonism of Y2 and Y4 recep-
tors attenuates anxiety- and depression-like behaviour (Redrobe
et al., 2003; Tschenett et al., 2003; Bacchi et al., 2006; Painsipp
et al., 2008b; Tasan et al., 2009, 2010), which indicates that NPY
signalling via Y2 and Y4 receptors has a negative impact on emo-
tional-affective behaviour. The opposing effects of Y2 and Y1
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synapses: NPY-mediated transmission via excitatory postsynaptic
Y1 receptors is counter-regulated by presynaptic Y2 receptor acti-
vation which inhibits the release of NPY and other transmitters
(Heilig, 2004; Chee and Colmers, 2008; Morales-Medina et al.,
2010).
Stress-induced changes in the amygdalar expression of NPY and
Y1 receptors and a speciﬁc anti-stress action of intraamygdalar
administration of NPY provide further evidence for an important
role of NPY in stress processing. For instance, acute restraint stress
decreases NPY expression in the amygdala, whereas intermittent
restraint stress over a 10 day period or exposure to a variable stress
paradigm for 1 week increases NPY expression within this struc-
ture (Thorsell et al., 1998, 1999; McGuire et al., 2011). In contrast,
exposure to footshocks for as little as 15 min is able to enhance the
amygdalar NPY expression as measured 2 weeks after the inter-
vention (de Lange et al., 2008). Y1 receptor expression in the amyg-
dala is increased by acute restraint stress, but left unaltered by
prolonged restraint over a period of 10 days (Mele et al., 2004),
whereas a single session of inescapable foot shock reduces amy-
gdalar Y1 receptor expression (Hendriksen et al., 2012). Transgenic
NPY overexpression attenuates anxiety-like responses induced by
restraint stress (Thorsell et al., 2000) much as repeated infusion
of NPY into the basolateral amygdala prevents stress-induced
behavioural changes in the social interaction test (Sajdyk et al.,
2008). Behavioural disturbances evoked by exposure of mice to
predator-scent stress are followed by a marked downregulation
of NPY in the hippocampus, periaqueductal grey and amygdala,
and intracerebral administration of NPY after stress exposure can
reduce the manifestation of stress-induced disruption of behaviour
(Cohen et al., 2012).
Given that NPY promotes stress resilience and aids the recovery
from stress, it is emerging that the NPY system also inﬂuences the
impact of stress on the gut–brain axis. Exposure of rats to water
avoidance stress lowers the plasma level of PYY, a change that is
associated with an increase in gastrointestinal motility (Liang
et al., 2012). Trinitrobenzene sulfonic acid-induced colitis in-
creases the NPY concentration in brain and plasma (Baticic et al.,
2011) whereas the expression of NPY mRNA in the brain remains
unaltered by Helicobacter pylori infection (Bercik et al., 2009). Gas-
trointestinal inﬂammation enhances anxiety- and depression-
related behaviour in a gender-dependent manner (Painsipp et al.,
2007, 2011a; Goehler et al., 2008), these effects being modiﬁed
by genetic deﬁciency of PYY and/or NPY. Speciﬁcally, the ability
of experimental colitis to enhance anxiety-related behaviour in
male mice is prevented by genetic deletion of PYY, but not NPY,
whereas the increase in depression-like behaviour which DSS
causes in female mice is abolished by NPY and PYY knockout (Pain-
sipp et al., 2011a). These observations attest to distinct roles of PYY
and NPY in the impact of intestinal inﬂammation on the gut–brain
axis. In addition, the depression-like phenotype of PYY knockout
animals (Painsipp et al., 2011a) suggests that alterations in the
expression of this gut hormone modify mood and stress coping.
The gender-related impact on behaviour may be related to a gen-
der-dependent implication of NPY in the stress-evoked release of
corticosterone (Forbes et al., 2012).
NPY is not only a stress mediator in the central nervous system
but also in the periphery. The stress-related implications of NPY
impact on many physiological systems including the cardiovascu-
lar system, the gastrointestinal tract, the immune system, metabo-
lism, and adaptation to stress (Hirsch and Zukowska, 2012). It is
obvious that these implications also affect gut–brain and brain–
gut communication. For instance, deletion of NPY alters gastroin-
testinal, feeding and corticosterone responses to restraint stress
in a gender-dependent manner (Forbes et al., 2012). Thus, the
stress-induced delay of upper gastrointestinal transit is morepronounced in female than in male NPY knockout mice. In addi-
tion, deletion of NPY exaggerates stress-induced defaecation and
reduces food intake, these effects being gender-independent (For-
bes et al., 2012). The stress-evoked release of corticosterone is en-
hanced by NPY deletion in male mice, and further experiments
indicate that NPY inhibits corticosterone release via peripheral
Y1 and Y2 receptor activation (Forbes et al., 2012).
3.7. PYY, PP and NPY regulate food intake and energy homeostasis
The gastrointestinal tract is a major endocrine organ that pro-
duces and releases a variety of messengers that act either in a par-
acrine or endocrine manner to coordinate digestion and regulate
metabolic homeostasis. The implications of PP, PYY and NPY in
gut–brain signalling are particularly well exempliﬁed by their ef-
fects on hunger, food intake, satiety and energy balance. Since
these roles have been extensively reviewed elsewhere (Murphy
and Bloom, 2006; Field et al., 2010; Kirchner et al., 2010; Zhang
et al., 2011), only some of the salient features are considered here.
PP and PYY function as satiety factors, slowing the gastrointestinal
transit of chyme, inhibiting further intake of food and modifying
metabolic and energy homeostasis (Field et al., 2010). Since these
actions take place, at least in part, in the brain, it should be con-
cluded that PP and PYY are able to signal to the brain.
PP, which is a preferential agonist at Y4 receptors, is released
postprandially from endocrine cells in pancreatic islets under vagal
cholinergic control (Schwartz, 1983; Murphy and Bloom, 2006;
Field et al., 2010). Peripheral administration of PP causes Y4 recep-
tor-dependent neuronal stimulation (c-Fos expression) in the
brainstem, hypothalamus and amygdala (Tasan et al., 2009). How-
ever, it is not clear whether PP can directly reach these cerebral
structures, although there is evidence that PP can enter the brain
(Inui et al., 1993; Banks et al., 1995) preferentially via circumven-
tricular organs such as the area postrema (Dumont et al., 2007). PP
causes a negative energy balance by decreasing food intake and
gastric emptying and by increasing energy expenditure, these ef-
fects also involving the vagus nerve (Asakawa et al., 2003; Murphy
and Bloom, 2006; Field et al., 2010). Knockout of the Y4 gene leads
to an increase in nocturnal feeding (Edelsbrunner et al., 2009b),
while transgenic overexpression of PP in mice reduces food intake
and body weight gain (Ueno et al., 1999). A reduction of food in-
take by PP is also seen in lean humans as well as in obese patients
with Prader-Willi syndrome (Berntson et al., 1993; Batterham
et al., 2003b). In the rodent brain, Y4 receptors have been localised
to the medulla, locus coeruleus, hypothalamus, hippocampus,
medial and basolateral amygdala, and ventral tegmental area
(Dumont et al., 1998; Parker and Herzog, 1999; Campbell et al.,
2003; Fetissov et al., 2004). While the role of Y4 receptors in syn-
aptic transmission is little known, Y4 receptors in the hypothala-
mus are involved in presynaptic inhibition of transmitter release
(Acuna-Goycolea et al., 2005).
PYY is released postprandially from intestinal L cells in propor-
tion to energy intake (Field et al., 2010) and in part truncated to
PYY3–36 which is the main circulating form of PYY and a relatively
selective Y2 receptor agonist. PYY and PYY3–36 inhibit gastric acid
secretion, gastrointestinal transit and food intake in rodents and
humans (Batterham et al., 2002; Challis et al., 2003; Nonaka
et al., 2003; Koda et al., 2005; Field et al., 2010). The anorectic ef-
fect of PYY3–36 is seen in both lean and obese subjects and in higher
doses is associated with nausea and vomiting (Batterham et al.,
2002, 2003a; Field et al., 2010). Food intake is inhibited by PYY3–
36 both via a stimulant effect on Y2 receptors on vagal afferent neu-
rons (Koda et al., 2005; Ueno et al., 2008) and an interaction with
Y2 receptors in the hypothalamus. This is consistent with the abil-
ity of PYY3–36 to gain access to the brain via circumventricular or-
gans such as the area postrema and subfornical organ (Dumont
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tain extent (Nonaka et al., 2003).
Within the brain, PYY3–36 reduces food intake primarily via acti-
vation of Y2 receptors in the arcuate nucleus which is an important
centre for integrating peripheral and central signals in the control
of appetite and energy homeostasis (Chee and Colmers, 2008). The
arcuate nucleus contains at least two populations of neurons that
are relevant in this respect: orexigenic neurons expressing NPY
and AgRP and anorexigenic neurons expressing pro-opiomelano-
cortin (POMC). These neurons send projections to various areas
of the hypothalamus (including the paraventricular nucleus) and
reciprocally inhibit the orexigenic/anorexigenic tone exerted by
NPY/AgRP neurons and POMC neurons, respectively (Chee and
Colmers, 2008). The anorectic effect of PYY3–36 is mediated primar-
ily by presynaptic Y2 receptors on NPY/AgRP neurons in the arcu-
ate nucleus, inhibiting their orexigenic action and disinhibiting
POMC neurons (Batterham et al., 2002; Murphy and Bloom,
2006; Ueno et al., 2008; Field et al., 2010). In addition, peripheral
infusion of PYY3–36, at doses mimicking the plasma levels of
PYY3–36 in the fed state, modulates neural activity in corticolimbic
areas (Batterham et al., 2007).
NPY is one of the most potent orexigenic peptides found in the
brain (Chee and Colmers, 2008; Zhang et al., 2011), the NPY/AgRP
neurons in the arcuate nucleus taking a central place in this re-
spect. Their orexigenic effect is primarily mediated by Y1 recep-
tors, although Y5 receptors also play a role (Zhang et al., 2011).
Selective ablation of NPY/AgRP neurons in the arcuate nucleus of
adult mice results in a life-threatening reduction of food intake
(Gropp et al., 2005; Luquet et al., 2005). These ﬁnding indicates
that feeding depends critically on the function of NPY/AgRP neu-
rons. Conversely, pathologies associated with a decrease in food in-
take such as experimental colitis lead to increased release of NPY
from the paraventricular nucleus of the hypothalamus (Ballinger
et al., 2001). Experiments with NPY knockout mice attest to a phys-
iological function of endogenous NPY in balancing energy intake
with physical activity-related energy expenditure (Edelsbrunner
et al., 2009a; Zhang et al., 2011). Besides the hypothalamus, many
other neuronal systems in the brain express NPY, and it is likely
that some of these NPY neurons (e.g., in the brainstem, nucleus
accumbens and corticolimbic system) likewise play a role in the
regulation of appetite and food intake.
3.8. PYY, PP and other gut hormones regulate anxiety and mood
Apart from regulating ingestion and energy homeostasis, gut
hormones such as ghrelin, PYY, glucagon-like peptide-1 and gluca-
gon-like peptide-2 have also an impact on emotional-affective
behaviour. Seen from an evolutionary point of view, co-regulation
of appetite and emotional state is an important strategy for sur-
vival, given that anxiety would be an adverse condition when there
is a need to seek food. Indeed, ghrelin which is released from the
upper gastrointestinal tract under conditions of hunger reduces
both anxiety-like and depression-related behaviour (Lutter et al.,
2008). Under fed conditions, behaviour is changed to a hedonic
state as observed when PYY3–36 is administered to reach postpran-
dial plasma concentrations of the peptide (Batterham et al., 2007).
Physiologically, however, emotion and mood under fed conditions
will be determined by the presence of a variety of gut hormones
that are released postprandially. Among these, glucagon-like
peptide-1 has been found to enhance anxiety-related behaviour
(Möller et al., 2002; Kinzig et al., 2003; Gulec et al., 2010), while
glucagon-like peptide-2 attenuates depression-like behaviour
(Iwai et al., 2009).
The ability of PYY to promote hedonic behaviour is supported
by the ﬁnding that knockout of PYY increases depression-like
behaviour but does not alter anxiety (Painsipp et al., 2011a). Thisﬁnding indicates that the gut hormone PYY or its major circulating
form, PYY3–36, is able to signal to the central nervous system, either
by gaining direct access to the brain (Nonaka et al., 2003; Dumont
et al., 2007) or by activating vagal afferent input to the brainstem
(Koda et al., 2005; Ueno et al., 2008). Although the biological ac-
tions of PYY3–36 are mediated primarily by Y2 receptors, it is not
yet understood which Y receptors mediate the antidepressant ef-
fect of gut-derived PYY, given that stimulation of Y2 receptors in
the brain increases anxiety- and depression-like behaviour (Heilig,
2004). In addition, knockout of Y2 receptors reduces anxiety-
related and depression-like behaviour and impairs learning and
memory (Tschenett et al., 2003; Redrobe et al., 2003, 2004b;
Painsipp et al., 2008b; Tasan et al., 2009, 2010). The anxiolytic
and antidepressant action of Y2 receptor knockout has been local-
ised to the deletion of presynaptic Y2 receptors in the central and
basolateral amygdala (Tasan et al., 2010).
PP whose biological actions are preferentially mediated by Y4
receptors is also able to inﬂuence emotional-affective behaviour.
Thus, anxiety- and depression-like behaviour is attenuated and
novelty-evoked locomotion increased in Y4 receptor knockout
mice (Painsipp et al., 2008b; Tasan et al., 2009). The anxiolytic-like
phenotype of Y4 receptor knockout mice is consistent with the
anxiogenic phenotype of PP-overexpressing mice (Ueno et al.,
2007). Since intracerebroventricular PP fails to alter anxiety-
related behaviour (Asakawa et al., 1999) while chronic peripheral
administration of PP reduces anxiety (Asakawa et al., 2003), it
would appear that PP modiﬁes anxiety- and depression-like behav-
iour through an action in the periphery or in the area postrema
outside the blood–brain barrier (Larsen and Kristensen, 1997;
Dumont et al., 2007; Tasan et al., 2009). This possibility is backed
by the ability of peripheral PP to induce Y4 receptor-dependent
c-Fos expression in brainstem, hypothalamus and amygdala and
by the expression of an appreciable number of Y4 receptors in
these regions (Tasan et al., 2009). In addition, knockout of the Y4
receptor is associated with an increase in the circulating level of
PP (Sainsbury et al., 2002).4. Conclusions
As outlined in this review, the study of the gut–brain axis has
proved to be of major relevance not only to gastroenterology but
also to experimental and clinical neuroscience, notably psychiatry.
The gut microbiota which is a symbiotic superorganism by itself,
the intestinal mucosa and the intestinal immune system issue mul-
tiple signals to the brain. These signals are carried by sensory neu-
rons, immune mediators, gut hormones and microbiota-derived
signalling molecules. In disease, this input from the gastrointesti-
nal tract gives rise to disturbances of digestion and gastrointestinal
function, pain and hyperalgesia, emotional-affective disturbances,
defective stress coping and cognitive impairment. In addition, the
autonomic and neuroendocrine outputs of the brain to the gut
may also be deranged.
The NPY-Y receptor system provides several targets whereby
gut–brain axis disorders could potentially be managed. The differ-
ent members of this peptide family, NPY, PYY and PP, operate both
as neural and endocrine messengers at distinct levels of the
gut–brain axis (Fig. 2). PYY and PP are exclusively expressed by
endocrine cells of the digestive system, whereas NPY is found at
all levels of the gut–brain and brain–gut axis. In the gastrointesti-
nal tract, NPY and PYY inhibit gastrointestinal motility and electro-
lyte secretion and may also interact with the intestinal microbiota.
Y1 receptors operated by NPY exert a proinﬂammatory action in
the gut, and the NPY-Y receptor system protects against distinct
behavioural disturbances caused by peripheral immune challenge,
attenuating the acute sickness response and preventing the
270 P. Holzer et al. / Neuropeptides 46 (2012) 261–274development of long-term depression. Similarly, NPY inhibits noci-
ceptive input from the periphery to the spinal cord and brainstem.
In the brain, NPY and its receptors (Y1, Y2, Y4, Y5) play important
roles in regulating locomotion, exploration, food intake, energy
homeostasis, anxiety, mood and stress resilience. This action pro-
ﬁle is in part shared by the gut hormones PP and PYY which signal
to the brain to attenuate food intake, anxiety and depression-
related behaviour.
These ﬁndings underscore an important role of the NPY-Y
receptor system at several levels of the gut–brain axis and support
the hypothesis that Y receptors are worthwhile targets for the ther-
apy of gut–brain axis disorders such as IBS. Unfortunately, the
pharmacology of the NPY-Y receptor system is developed only to
a limited extent so that many therapeutic opportunities arising
from the implications of the NPY-Y receptor system in the gut–
brain axis cannot yet be thoroughly evaluated. However, gene
knockout and transgenic approaches attest to the validity of the
NPY system as a therapeutic target, a conclusion that is increas-
ingly supported by clinical studies. Given that the NPY-Y receptor
system operates as a multi-level homeostatic mechanism, pharma-
cological manipulation of this system may have considerable ther-
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